1. Home
  2. OPHC vs SCYX Comparison

OPHC vs SCYX Comparison

Compare OPHC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

N/A

Current Price

$5.46

Market Cap

67.5M

Sector

Finance

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.65

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPHC
SCYX
Founded
2000
1999
Country
United States
United States
Employees
98
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5M
60.4M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
OPHC
SCYX
Price
$5.46
$4.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.50
$3.00
AVG Volume (30 Days)
21.4K
354.4K
Earning Date
04-24-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
0.20
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$17,095.98
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
$27.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$0.57
52 Week High
$5.64
$5.62

Technical Indicators

Market Signals
Indicator
OPHC
SCYX
Relative Strength Index (RSI) 55.12 79.82
Support Level $5.40 $0.67
Resistance Level $5.60 N/A
Average True Range (ATR) 0.08 0.21
MACD -0.01 0.48
Stochastic Oscillator 84.76 81.15

Price Performance

Historical Comparison
OPHC
SCYX

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: